Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis

Inclusion Criteria:

1. Patients voluntarily participate in studies and sign informed consent forms
2. Ages 2-80 years (with cut-off values) male and female
3. One of the following is true （1）In patients with cytomegalovirus retinitis afterhematopoietic stem cell transplantation/cord blood transplantation, the white bloodcell count is less than 4× 10^9/L, and the platelet count ranges are 25× 10^9/L≤PLT<100×10^9/L，Intravitreal injection carries a greater risk of infection andbleeding, and is unable to administer systemic medication due to the bone marrowsuppression of antiviral drugs, or systemic medication for severe CMV retinitis cannotbe well controlled; （2）In patients with CMVR with AIDS, the CD4+ T cell count is lessthan 100/μl, there is a great risk of infection with intravitreal injection, and thesystemic medication of severe CMV retinitis cannot be well controlled.

Exclusion Criteria:

• Eye condition

1. The presence of refractive interstitial opacification affects fundus observation;
2. Intravitreal ganciclovir or sodium phosformate injections were performed within 1week prior to baseline;
3. Other diseases that can affect visual function such as syphilis-related eyediseases, acute retinal necrosis, congenital glaucoma, congenital corneallesions, congenital macular degeneration, etc.

• General condition

1. Severe neutropenia (<0.5×10^9) or severe thrombocytopenia (< 25× 10^9/L);
2. Other investigators judged patients who were not suitable for enrollment;